Advancing Adjuvants for Mycobacterium tuberculosis Therapeutics

Area of Science:

• Immunology and Vaccinology
• Infectious Diseases

Background:

• Tuberculosis (TB) remains a leading global cause of death from a single infectious agent.
• The current Bacillus Calmette-Guérin (BCG) vaccine provides limited protection against pulmonary TB.
• Recent advances show promise for alternative BCG administration and subunit/adjuvant vaccines.

Purpose of the Study:

• To address the lack of development in TB-targeted vaccine adjuvants.
• To present key areas identified for advancing TB adjuvants, based on a 2020 NIAID workshop.
• To guide future research towards more efficacious TB vaccines.

Main Methods:

• Review of findings and discussions from the NIAID workshop 'Advancing Vaccine Adjuvants for Mycobacterium tuberculosis Therapeutics'.
• Detailed examination of four critical areas identified for TB adjuvant advancement.
• Synthesis of current knowledge and identification of future research directions.

Main Results:

• Four essential areas for advancing TB adjuvants were identified: correlates of protective immunity, targeting specific immune cells, immune evasion mechanisms, and animal models.
• These areas represent crucial knowledge gaps and research priorities for TB vaccine development.
• Progress in these areas is necessary for the next generation of TB vaccines.

Conclusions:

• Developing effective TB adjuvants is critical for improving current TB vaccine efficacy.
• Focused research in the four identified areas will accelerate the development of new TB vaccines.
• This review provides a roadmap for advancing TB adjuvant research and ultimately combating tuberculosis.